Evidence map›Paper›PMID 35902159›Full record

ArticleJACC. Heart failure2022

Sodium-Glucose Co-Transporter-2 Inhibitors and Cardiac Outcomes Among Patients Treated With Anthracyclines.

Carlos A Gongora, Zsofia D Drobni, Thiago Quinaglia Araujo Costa Silva, Amna Zafar, Jingyi Gong, Daniel A Zlotoff, Hannah K Gilman, Sarah E Hartmann, Supraja Sama, Sofia Nikolaidou and 9 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JACC. Heart failure, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 95 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
95citing papers in PubMed, 5 pooled it
18.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

95 citing papers in PubMed, 5 syntheses or guidelines pooled it, 147 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. From Computational Prediction toResearch square · 2026
    Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Observational
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review

35 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 6 institutions in 3 countries.

Carlos A GongoraCardiovascular Imaging Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA; Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Zsofia D DrobniCardiovascular Imaging Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA; Heart and Vascular Center, Semmelweis University, Budapest, Hungary.
Thiago Quinaglia Araujo Costa SilvaCardiovascular Imaging Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Amna ZafarCardiovascular Imaging Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA; Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Jingyi GongDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Daniel A ZlotoffCardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Hannah K GilmanCardiovascular Imaging Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Sarah E HartmannCardiovascular Imaging Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Supraja SamaCardiovascular Imaging Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Sofia NikolaidouCardiovascular Imaging Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Giselle Alexandra Suero-AbreuCardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Eric JacobsenMedical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Jeremy S AbramsonCenter for Lymphoma, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Ephraim HochbergCenter for Lymphoma, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Jeffrey BarnesCenter for Lymphoma, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Philippe ArmandMedical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Paaladinesh ThavendiranathanTed Rogers Program in Cardiotoxicity Prevention, Peter Munk Cardiac Centre, Toronto General Hospital, University of Toronto, Toronto, Canada.
Anju NohriaDepartment of Cardiology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Tomas G NeilanCardiovascular Imaging Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA; Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. Electronic address: tneilan@mgh.harvard.edu.
Harvard University · USMassachusetts General Hospital · USDana-Farber Cancer Institute · USBrigham and Women's Hospital · USSemmelweis University · HUUniversity of Toronto · CA

Funding

Cardiac MR and CT ResearchT32HL076136 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI NEILAN, TOMAS G · 2004 to 2019
$4.9M
STOP-CA: Statins to prevent Cardiotoxicity from AnthracyclinesR01HL130539 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI NEILAN, TOMAS G, SCHERRER-CROSBIE, MARIELLE · 2016 to 2020
$3.2M
Mechanisms of Cardiac Dysfunction in HIV and the Effect of StatinsR01HL137562 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI NEILAN, TOMAS G, ZANNI, MARKELLA V. · 2017 to 2020
$2.7M
Cardiovascular Diseases among Patients with Cancer and Patients living with HIVK24HL150238 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI Tomas G Neilan · 2020 to 2026
$883k
NHLBI NIH HHS K24 HL150238NHLBI NIH HHS R01 HL130539NHLBI NIH HHS R01 HL137562NHLBI NIH HHS T32 HL076136
6 · The paper itself

Abstract

backgroundSodium-glucose co-transporter-2 (SGLT2) inhibitors improve outcomes among patients with established heart failure. Despite supportive basic science studies, there are no data on the value of SGLT2 inhibitors among patients treated with anthracyclines.

objectivesThis study sought to test the cardiac efficacy and overall safety of SGLT2 inhibitors in patients treated with anthracyclines.

methodsThis study identified 3,033 patients with diabetes mellitus (DM) and cancer who were treated with anthracyclines. Cases were patients with cancer and DM who were on SGLT2 inhibitor therapy during anthracycline treatment (n = 32). Control participants (n = 96) were patients with cancer and DM who were also treated with anthracyclines, but were not on an SGLT2 inhibitor. The primary cardiac outcome was a composite of cardiac events (heart failure incidence, heart failure admissions, new cardiomyopathy [>10% decline in ejection fraction to <53%], and clinically significant arrhythmias). The primary safety outcome was overall mortality.

resultsAge, sex, ethnicity, cancer type, cancer stage, and other cardiac risk factors were similar between groups. There were 20 cardiac events over a median follow-up period of 1.5 years. The cardiac event incidence was lower among case patients in comparison to control participants (3% vs 20%; P = 0.025). Case patients also experienced lower overall mortality when compared with control participants (9% vs 43%; P < 0.001) and a lower composite of sepsis and neutropenic fever (16% vs 40%; P = 0.013).

conclusionsSGLT2 inhibitors were associated with lower rate of cardiac events among patients with cancer and DM who were treated with anthracyclines. Additionally, SGLT2 inhibitors appeared to be safe. These data support the conducting of a randomized clinical trial testing SGLT2 inhibitors in patients at high cardiac risk treated with anthracyclines.

Indexed as

Cardiovascular DiseasesDiabetes Mellitus, Type 2Heart FailureSodium-Glucose Transporter 2 InhibitorsSymportersAnthracyclinesGlucoseHumansSodiumAnthracyclinesGlucoseSodiumSodium-Glucose Transporter 2 InhibitorsSymportersanthracycline-induced cardiomyopathycardiotoxicitycardiovascular outcomeschemotherapy doxorubicinheart failureSGLT2 inhibitors

Identifiers

PMID35902159
PMCPMC9638993
OpenAlexW4288032971

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.